GC Medical Science

At a glance

GC Medical Science filed 34 disclosures in the last 12 months, including 9 insider, 5 earnings and 2 5% holder. The most recent key filing was on Oct 30: Operating profit ₩1.1B, up 20.4% YoY. Revenue ₩27B, up 2.3% YoY.

Revenue for 2025 was ₩108B, up 4.4% on 2024. Operating margin was 2.7% against 2.2% a year earlier. Debt was 95% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩50.7B and operating profit of ₩1B.

The 2025 annual report lists 131 employees with an average tenure of 6.2 years and average pay of ₩47M, #1586 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩254M each on average. It paid no cash dividend for 2025. ㈜녹십자 and related parties held 51.77% at year end.

From the 2025 annual report

Staff: 131 (94 men, 37 women), of whom 18 on fixed-term contracts. Total pay for the year: ₩6.2B. Directors and auditors: 5, paid ₩1.3B in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜녹십자 holds 40.32%; with 10 related parties the group holds 51.77% of common shares at year end (from 51.73% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary